24 – 25 October, 2024 | Embassy of France, Washington, D. C., USA

A Multi-stakeholder Multi-specialty
NASH Trialists Think Tank

Metabolic, hepatology, nephrology & cardiovascular cross-talk

19 - 20 October, 2023

Georgetown University, Leavey Center, Washington, D. C.
ACCESS LIVE STREAM
DOWNLOAD AGENDA
DOWNLOAD AGENDA

Download Virtual Connection Guide

Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health
Download Agenda
Organized by
assets-05
In collaboration with
cvc
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Download Agenda
Download Agenda
Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health

19 – 20 October,
2023

Embassy of France
4101 Reservoir Road, NW – Washington, D.C. – 20007

Download Agenda
Organized by
In collaboration

Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

assets-04
Download Agenda
Organized by
assets-05
In collaboration with
cvc
assets-07
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Overview Topics Speakers Learning Objectives Agenda Sponsors
Overview
MOSAIC - Global NASH/MASH Trialist Forum
brings together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about clinical trials through cross-talks.
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
NASH/MASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH/MASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH/MASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
Learning Objectives
Why should you attend?
  • list icon
    Networking opportunities
  • list icon
    Think Tank focused Workshops
  • list icon
    Latest trials updates
  • list icon
    Patient participation
View more
Chairs
Javed Butler (USA)
Javed Butler
USA
Stephen Harrison
USA
Veronica Miller
USA
Arun Sanyal
USA
chair-eclipse
Faiez Zannad
France
See all Speakers
Topics
  • NASH/MASH – Cardiovascular intersections
  • Epidemiology, disease mechanisms
  • Non-invasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH/MASH trials
View full agenda
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
View full agenda
Topics
  • NASH – Cardiovascular Intersection
  • Epidemiology, disease mechanisms
  • NonInvasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH trials
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
View full agenda
Become a sponsor